There are currently 5 FDA-approved stimulants for the treatment of narcolepsy in patients ages 6 and older, while there is only one psychotropic, duloxetine, which is FDA-approved for generalized anxiety disorder in child and adolescent populations. Due to lack of clinical trials in pediatric psychiatric medicine, the PMHNP frequently prescribes off-label based on existing data on adult treatment response, adjusting doses according to weight and variability in metabolic profile. As a future psychiatric nurse practitioner, do you anticipate FDA-approval influencing your prescribing strategies for this specialized population? Why or why not. Give at least two rationales for your response, then respond to two other classmates.
PLACE THIS ORDER OR A SIMILAR ORDER WITH NURSING TERM PAPERS TODAY AND GET AN AMAZING DISCOUNT
